53571-U
Ascentis® Express 90 Å F5 (2.7 μm) HPLC Columns
L × I.D. 15 cm × 2.1 mm, HPLC Column
别名:
Core-shell (SPP) Fused Core PFP HPLC column
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
15 cm × 2.1 mm
Particle size:
2.7 μm
Matrix active group:
PFP (pentafluorophenyl) phase
Pore size:
90 Å pore size
Matrix:
Fused-Core particle platform, superficially porous particle
产品名称
Ascentis® Express F5, 2.7 μm HPLC 色谱柱, 2.7 μm particle size, L × I.D. 15 cm × 2.1 mm
material
stainless steel column
Quality Segment
agency
suitable for USP L43
product line
Ascentis®
feature
endcapped
manufacturer/tradename
Ascentis®
packaging
1 ea of
parameter
60 °C temp. range, 600 bar max. pressure (9000 psi)
technique(s)
HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable
L × I.D.
15 cm × 2.1 mm
surface area
135 m2/g
impurities
<5 ppm metals
matrix
Fused-Core particle platform, superficially porous particle
matrix active group
PFP (pentafluorophenyl) phase
particle size
2.7 μm
pore size
90 Å pore size
operating pH
2-8
application(s)
food and beverages
separation technique
reversed phase
General description
由于存在电负性氟，Ascentis Express F5 的五氟苯基丙基固定相可提供具有缺电子苯环的稳定反相填料。除了形成 pi-pi 和温和的空间相互作用外，F5 相也通过极性相互作用保留化合物。Ascentis Express F5 可用于碱性、酸性或中性化合物，选择性与 C18 不同。
Application
- Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.: This study employs the Ascentis® Express F5, 2.7 μm HPLC Column to enhance the resolution and sensitivity in the analysis of lumacaftor and ivacaftor, critical medications for treating cystic fibrosis. The method provides significant insights into the stability and degradation pathways of these drugs, facilitating improved drug formulation and storage conditions (Ozcan et al., 2023).
- Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product.: Utilizing the Ascentis® Express F5, 2.7 μm HPLC Column, this research develops advanced analytical techniques for tasimelteon, a treatment for non-24-hour sleep-wake disorder. The methods ensure accurate quantification and stability assessment, crucial for clinical efficacy and patient safety (Ozcan et al., 2020).
Legal Information
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Ascentis® Express F5, 2.7 μm HPLC 色谱柱